Author Affiliatons: Department of Radiation Oncology, Duke University Medical Center, Durham, NC.
Adenocarcinoma of the prostate is the most commonly diagnosed malignancy
in men in the United States, with 220 900 new cases and 28 900 deaths
from the disease reported in 2003.1 Despite
the widespread use of serum prostate-specific antigen (PSA) to screen for
prostate cancer in this country, approximately 25% of men treated with radical
prostatectomy for tumors presumed localized to the prostate will be found
to have extension of cancer beyond the capsule of the gland.2 These
men are at high risk for subsequent recurrence of their disease.
Anscher MS. Salvage Radiotherapy for Recurrent Prostate CancerThe Earlier the Better. JAMA. 2004;291(11):1380-1382. doi:10.1001/jama.291.11.1380